J-Plasma Enrollment in Clinical StudyBovie Medical Corporation, the developer of J-Plasma, has now announced that it has enrolled the first patient in an IDE (Investigational Device Exemption) clinical study in the US. This study will reveal more facts about the efficacy and safety of J-Plasma technology for dermal skin resurfacing. This comprehensive clinical study will be carried out at multiple centers, and will evaluate the benefits of J-Plasma procedure for the diminishing of facial wrinkles, creases and rhytides. The study will enroll 55 eligible patients and will be performed at up to five investigational centers. Enrolled patients will go through one treatment with the J-Plasma technique. Their severity of facial wrinkles will be assessed at baseline and thereafter at every follow up point. According to Charlie Goodwin, CEO of Bovie Medical, the developer’s long-term clinical strategy aims to expand the clinical indications of J-Plasma for use in aesthetic enhancement, starting with dermal skin resurfacing procedures. With the enrollment of the first patient in the skin resurfacing clinical study, the company has now achieved an important milestone in this journey. Bovie Medical will utilize the results of this study to demonstrate the aesthetic benefits and safety of J-Plasma and submit the technology to the US FDA for their review and clearance.
Why choose J-Plasma dermal skin resurfacing?Patients choose J-Plasma med spa procedure for skin rejuvenation due to the following reasons:
- Improved results achieved in a minimally invasive way
- Comfortable in-office procedure
- Can be completed in about one hour
- Performed using only local anesthesia
- Almost no visible incisions or scarring